Comparative Pharmacology
Head-to-head clinical analysis: METRETON versus METROGEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METRETON versus METROGEL.
METRETON vs METROGEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antihistamine and mast cell stabilizer. Competitively inhibits histamine at H1 receptors and prevents release of histamine and other mediators from mast cells.
Metronidazole, after intracellular reduction, forms cytotoxic metabolites that disrupt bacterial DNA and inhibit nucleic acid synthesis. It also has anti-inflammatory and immunomodulatory effects in rosacea.
1-2 mg/kg intramuscularly or intravenously every 6-8 hours as needed; maximum 100 mg per dose.
Topical application of 1% gel: Apply a thin layer to affected area twice daily; intravaginal 0.75% gel: one applicatorful (5 g) once daily at bedtime.
None Documented
None Documented
Terminal elimination half-life is 24-36 hours; increased in renal impairment (up to 60 hours in anuria)
8-10 hours (terminal); increased to 20-30 hours in hepatic impairment.
Renal (80-90% as unchanged drug and metabolites), biliary/fecal (10-20%)
Renal: 60-80% as unchanged drug; fecal: 6-15%; biliary: minor.
Category C
Category C
Antibiotic (Nitroimidazole)
Antibiotic (Nitroimidazole)